Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1 add-on to growth hormone in children with idiopathic growth hormone deficiency and poor first-year response
2010-020742-10Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Nov 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in idiopathic growth hormone deficiency (I-GHD) comparing Mecasermin + somatropin with Somatropin alone (2 arms). Primary endpoint: Difference in mean height velocity after 1 year of treatment. Started Nov 2010; status: terminated.
02
Drugs
mecaserminsomatropin
03
Conditions
idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on 2010-020742-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020742-10.